Neuroblastoma, the most common solid tumor in children, includes a particularly favorable subtype known as MS neuroblastoma, which is seen in infants under 12 months with metastasis limited to the liver, skin, or bone marrow. Treatment for MS neuroblastoma involves observation or limited chemotherapy typically administered through central venous catheters (CVCs), which carry risks of bloodstream infections and other complications. We describe a female infant with MS neuroblastoma who developed MSSA bacteremia, deep vein thrombosis, and respiratory distress following chemotherapy via a PICC line, requiring its removal. A peripheral IV (PIV) was used for the second round of chemotherapy without complication, suggesting a safer alternative to central lines. Many studies support PIV-administered chemotherapy as a viable option, citing reduced infection rates, fewer complications, and lower costs. While not yet standard practice, PIV chemotherapy administration may be beneficial for patients with high CVC-related risks, warranting further research to establish its role in short-term treatment regimens.